FDA OKs Isis Orphan Drug Amid Shareholder's Safety Suit
The Food and Drug Administration announced Tuesday that it approved Kynamro as an orphan drug treatment for a rare type of high cholesterol, a drug whose safety concerns prompted a shareholder...To view the full article, register now.
Already a subscriber? Click here to view full article